Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells.

Yao-Borengasser A, Monzavi-Karbassi B, Hedges RA, Rogers LJ, Kadlubar SA, Kieber-Emmons T.

Oncol Rep. 2015 Mar 30. doi: 10.3892/or.2015.3880. [Epub ahead of print]

PMID:
25823469
2.

Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.

Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B.

Sci Rep. 2015 Feb 23;5:8534. doi: 10.1038/srep08534.

3.

Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry.

Starlard-Davenport A, Orloff MS, Dhakal I, Penney RB, Kadlubar SA.

PLoS One. 2015 Feb 3;10(2):e0117347. doi: 10.1371/journal.pone.0117347. eCollection 2015.

4.

Pharmacogenetics of SULT1A1.

Daniels J, Kadlubar S.

Pharmacogenomics. 2014 Nov;15(14):1823-1838.

PMID:
25493573
5.

Cross-sectional study to assess the association of population density with predicted breast cancer risk.

Lee JY, Klimberg S, Bondurant KL, Phillips MM, Kadlubar SA.

Breast J. 2014 Nov-Dec;20(6):615-21. doi: 10.1111/tbj.12330. Epub 2014 Sep 8.

PMID:
25200109
6.

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples.

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML.

Pharmgenomics Pers Med. 2014 Jul 14;7:163-71. doi: 10.2147/PGPM.S62238. eCollection 2014.

7.

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, Finel M, Kadlubar SA, Radominska-Pandya A.

Drug Metab Dispos. 2014 Sep;42(9):1392-400. doi: 10.1124/dmd.114.058016. Epub 2014 Jun 10.

PMID:
24917585
8.

High-circulating Tie2 is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S.

Am J Clin Oncol. 2014 Feb 26. [Epub ahead of print]

PMID:
24577164
9.

Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells.

Yao-Borengasser A, Rogers LJ, Edavana VK, Penney RB, Yu X, Dhakal IB, Williams S, Kadlubar SA.

BMC Clin Pathol. 2014 Jan 6;14(1):1. doi: 10.1186/1472-6890-14-1.

10.

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.

Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S.

Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013.

11.

Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects.

Kadlubar SA.

J Surg Oncol. 2013 Nov;108(6):335-6. doi: 10.1002/jso.23404. Epub 2013 Sep 20. No abstract available.

PMID:
24142574
12.

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue.

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S.

Pharmgenomics Pers Med. 2013 Sep 9;6:99-103. doi: 10.2147/PGPM.S49199. eCollection 2013.

13.

Sulfotransferase genetic variation: from cancer risk to treatment response.

Daniels J, Kadlubar S.

Drug Metab Rev. 2013 Nov;45(4):415-22. doi: 10.3109/03602532.2013.835621. Epub 2013 Sep 6. Review.

14.

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects.

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S.

Pharmgenomics Pers Med. 2013;6:19-24. doi: 10.2147/PGPM.S36579. Epub 2013 Mar 6.

15.

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer.

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF.

Pharmgenomics Pers Med. 2013;6:9-17. doi: 10.2147/PGPM.S35949. Epub 2013 Mar 1.

16.

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S.

Drug Metab Dispos. 2013 Apr;41(4):870-7. doi: 10.1124/dmd.112.048157. Epub 2013 Jan 31.

17.

Differential promoter activities of functional haplotypes in the 5'-flanking region of human sulfotransferase 1A1.

Lin ZN, Lin YC, Zhang X, Kadlubar S, Tuo J, Green B, Deng H, Ning B.

J Biochem Mol Toxicol. 2012 Oct;26(10):422-8. doi: 10.1002/jbt.21437.

PMID:
23080433
18.

Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer.

Zhang X, Lin J, Wu X, Lin Z, Ning B, Kadlubar S, Kadlubar FF.

Int J Mol Epidemiol Genet. 2012;3(3):228-36. Epub 2012 Aug 31.

19.

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1.

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S.

Pharmgenomics Pers Med. 2011 Nov 16;4:137-145.

20.

Interleukin genes and associations with colon and rectal cancer risk and overall survival.

Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML.

Int J Cancer. 2013 Feb 15;132(4):905-15. doi: 10.1002/ijc.27660. Epub 2012 Jun 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk